The randomized, double-blind, controlled trial VIGOR (Vioxx Gastrointestinal Outcomes Research) compared the efficacy and safety of rofecoxib (Vioxx), a COX-2 inhibitor, with naproxen, a NSAID, in patients with rheumatoid arthritis. Here, PTGS2 is linked to rheumatoid arthritis.